• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CGTX

    Cognition Therapeutics Inc.

    Subscribe to $CGTX
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: cogrx.com

    Recent Analyst Ratings for Cognition Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    11/3/2021$27.00Buy
    B. Riley Securities
    11/3/2021$22.00Outperform
    Oppenheimer
    See more ratings

    Cognition Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Khattar Jack A. was granted 34,000 shares, increasing direct ownership by 234% to 48,500 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:22:07 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wallace Peggy was granted 34,000 shares, increasing direct ownership by 65% to 86,461 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:21:38 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Richstone Ellen B was granted 34,000 shares, increasing direct ownership by 139% to 58,500 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:21:06 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Monia Brett P was granted 34,000 shares, increasing direct ownership by 234% to 48,500 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:20:50 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kreis Leslie W. was granted 34,000 shares (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/20/25 5:41:08 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Fletcher Aaron G.L. was granted 34,000 shares (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/20/25 5:38:56 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 9,692 shares, decreasing direct ownership by 2% to 404,710 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      5/2/25 5:53:52 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 6,619 shares, decreasing direct ownership by 0.74% to 887,066 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/18/25 4:29:37 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Caggiano Anthony covered exercise/tax liability with 5,296 shares, decreasing direct ownership by 1% to 418,554 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/18/25 4:28:44 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 1,723 shares, decreasing direct ownership by 0.41% to 414,402 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/18/25 4:28:23 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cognition Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

      12/19/24 7:33:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral

      7/30/24 6:19:11 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target

      B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00

      11/3/21 8:37:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Cognition Therapeutics with a new price target

      Oppenheimer initiated coverage of Cognition Therapeutics with a rating of Outperform and set a new price target of $22.00

      11/3/21 6:18:21 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/4/25 4:11:53 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ricciardi Lisa bought $9,975 worth of shares (5,700 units at $1.75), increasing direct ownership by 2% to 291,345 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      3/14/24 4:34:10 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. SEC Filings

    See more
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/20/25 4:01:35 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/3/25 7:39:52 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/2/25 6:01:27 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      5/8/25 7:35:46 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cognition Therapeutics Inc.

      10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      5/7/25 7:45:34 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      5/7/25 7:36:04 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Cognition Therapeutics Inc.

      DEFA14A - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      4/28/25 4:11:14 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Cognition Therapeutics Inc.

      DEF 14A - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      4/28/25 4:07:43 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Cognition Therapeutics Inc.

      424B5 - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      3/20/25 4:08:32 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Cognition Therapeutics Inc.

      S-8 - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      3/20/25 7:51:43 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

      - Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive clinical and biomarker effects of zervimesine in the low p-tau217 population in Phase 2 Alzheimer's disease study - PURCHASE, N.Y., July 16, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that James E. Galvin, MD, MPH will present results from the Phase 2 ‘SHIMMER' study of zervimesine (CT1812) in dement

      7/16/25 7:30:51 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

      PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. The objective of this meeting was to review results from the Phase 2 study of zervimesine (CT1812) and to discuss plans for a Phase 3 program that would support a new drug application (NDA) for zervimesine as a treatment for Alzheimer's disease. Lisa Ricciardi, president and CEO of Cognition, stated, "We discussed the results from the Phase 2 ‘SHINE' Study in Alzheimer's disease and our p

      7/10/25 7:30:53 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

      PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer's Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. Christopher van Dyck, MD, stated, "This is an important milestone for the study and is a testament to the commitment of the investigators and site teams and a high level of interest from participants in an or

      7/1/25 7:30:23 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

      - End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 'SHINE' study (NCT03507790) of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease. In addition, proposed

      6/25/25 7:30:23 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

      Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute   PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provide

      6/3/25 7:30:02 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

      PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervime

      5/9/25 7:30:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

      Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine's potential across degenerative disease indications PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported topline results today from the Phase 2 COG2201 ‘MAGNIFY' trial of zervimesine (CT1812) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The results show zervimesine-treated participants had 28.6% slower GA

      5/8/25 7:30:31 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

      - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB

      5/7/25 7:30:15 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

      PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference taking place April 1-5, 2025 in Vienna, Austria. In her presentation, Mary Hamby, Ph.D., VP of research at Cognition, compared changes in key proteins, called biomarkers, in the entire study population with changes observed in participants who began the study with lower levels of a protein c

      4/1/25 7:30:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

      PURCHASE, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, will be presenting biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference taking place April 1-5, 2025 in Vienna, Austria. Mary Hamby, Ph.D., Cognition Therapeutics' VP of research will present findings from the SHINE study during a podium presentation at the conference. Her address will focus on the analysis of key proteins, called biomarkers, that were

      3/25/25 7:30:57 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

      PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard

      5/1/23 7:30:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

      PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,

      10/11/22 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

      PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c

      11/3/21 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

      - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB

      5/7/25 7:30:15 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

      Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year en

      3/20/25 7:00:26 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

      PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Toll-Free Dial-in Number: (877) 704-4453International Dial-In Number: (201) 389-0920Conference I

      3/13/25 4:05:30 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

      - Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses ac

      12/18/24 7:22:43 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

      - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition") today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "In the th

      11/13/24 7:30:45 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

      - Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology -  - ADAS-Cog 11 scores showed 95% slowing of decline -  - MMSE scores showed 108% slowing of decline -  - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 -  - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented a pre-specified analysis of data fro

      10/29/24 12:55:00 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

      - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - PURCHASE, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "We announced favorable resul

      8/8/24 7:00:53 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics to Report Second Quarter 2024 Financial Results

      PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference CallDate / TimeAugust 8, 2024 at 8:30am ET / 5:30am PTTelephone Access: US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871U

      8/5/24 7:30:19 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

      PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Participant Toll-Free Dial-in Numb

      3/15/24 7:30:59 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

      Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer's Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer's Disease Published Data from SNAP Study Affirming Target Engagement of Sigma-2 (σ-2) Receptor Patient Dosing Commenced in MAGNIFY Study for Geographic Atrophy PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2023 an

      8/8/23 7:00:18 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cognition Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      2/7/24 7:01:44 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cognition Therapeutics Inc.

      SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      1/19/24 3:07:49 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      11/13/23 5:25:24 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      2/15/23 7:02:36 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      12/5/22 5:27:07 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cognition Therapeutics Inc.

      SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      11/18/22 7:21:19 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      2/1/22 4:03:11 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Cognition Therapeutics Inc.

      SC 13D - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      10/25/21 4:06:44 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care